Cerebrospinal Fluid Anti-Amyloid-Beta; Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation

Maria Carmona-Iragui, Ana Fernández-Arcos, Daniel Alcolea, Fabrizio Piazza, Estrella Morenas-Rodriguez, Sofia Antón-Aguirre, Isabel Sala, Jordi Clarimon, Oriol Dols-Icardo, Valle Camacho, Frederic Sampedro, Josep Munuera, Fidel Nuñez-Marin, Alberto Lleó, Juan Fortea, Beatriz Gómez-Ansón, Rafael Blesa

Producció científica: Contribució a una revistaArticleRecercaAvaluat per experts

40 Cites (Scopus)

Resum

© 2016 - IOS Press and the authors. All rights reserved. We report a biomarker and genetic evaluation of four patients with cerebral amyloid angiopathy-related inflammation (CAA-ri) treated with corticosteroids. Patients presented with focal symptomatology and cognitive impairment. MRI revealed cortical microbleeds and asymmetrical hyperintense white matter lesions (WML). Cerebrospinal fluid (CSF) biomarker analyses showed increased anti-Aβ autoantibodies, t-Tau, and p-Tau and decreasedAβ40 andAβ42. After treatment, focal symptomatology disappeared, andWMLand anti-Aβautoantibodies decreased. TheAPOEε4 allelewas overrepresented. Florbetapir-PET showed cortical deposition with lower retention in swollen areas. In the case of suspected CAA-ri, both CSF anti-Aβ autoantibodies levels and Florbetapir-PET could provide highly useful data to guide the correct diagnosis.
Idioma originalEnglish
Pàgines (de-a)1-7
RevistaJournal of Alzheimer's Disease
Volum50
Número1
DOIs
Estat de la publicacióPublicada - 1 de gen. 2016

Fingerprint

Navegar pels temes de recerca de 'Cerebrospinal Fluid Anti-Amyloid-Beta; Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation'. Junts formen un fingerprint únic.

Com citar-ho